Skip to main content
. 2022 Feb 24;28(3):591–598. doi: 10.1038/s41591-022-01707-4

Fig. 5. Subgroup analyses of the effects of tirzepatide on the adjudication-confirmed composite MACE-4.

Fig. 5

Data are point estimates of HR (illustrated by the diamond symbol) and range of two-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). bDerived from a Cox proportional hazards model with treatment (pooled tirzepatide versus pooled comparator), the subgroup variable and the treatment-by-subgroup interaction term as fixed effects, stratified by study-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum) for subgroups other than stratum. Pre-specified subgroup analyses were by sex, age and baseline HbA1c; the rest of the analyses were post hoc. P value is from the Wald chi-square test. N, number of participants in the subgroup in population; n, number of participants in the specified category.